Product Name: Cytokeratin 7 Antibody
Species Reactivity: Human
Tested Applications: Flow, IF, IHC-P
Applications: Flow Cytometry: 0.5-1ug/10e6 cells in 0.1mlImmunofluorescence: 0.5-1 ug/mlImmunohistochemistry (FFPE): 0.5-1 ug/ml for 30 min at RTOptimal dilution of the Cytokeratin 7 antibody should be determined by the researcher.
User Note: Optimal dilutions for each application to be determined by the researcher
Predicted Molecular Weight:
Immunogen: Full-length human CK7 protein was used as the immunogen for the Cytokeratin 7 antibody.
Host Species: Rabbit
Purification: Protein A affinity chromatography
Physical State: Liquid
CAS NO.: 1431697-78-7
Product: CAL-130 (Hydrochloride)
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Conditions: Aliquot and Store at -20C. Avoid freez-thaw cycles.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: Keratin, type II cytoskeletal 7, Cytokeratin-7, CK-7, Keratin-7, K7, Sarcolectin, Type-II keratin Kb7, KRT7, SCL
Accession NO.:
Protein Ino:
Official Symbol: KRT7
Geneid: 3855
Background: Cytokeratin-7 (CK7) is a member of the keratin gene family. The type II cytokeratins consist of basic or neutral proteins which are arranged in pairs of heterotypic keratin chains coexpressed during differentiation of simple and stratified epithelial tissues. CK7 is specifically expressed in the simple epithelia lining the cavities of the internal organs and in the gland ducts and blood vessels. It is found in simple glandular epithelia, and in transitional epithelium. Epithelial cells of the lung and breast both contain CK7, but some other glandular epithelia, such as those of the colon and prostate, do not. Because the protein is found in both healthy and neoplastic cells, antibodies to CK7 can be used in immunohistochemistry to distinguish ovarian and transitional cell carcinomas from colonic and prostate cancers, respectively. It is commonly used together with CK20 when making such diagnoses. [Wiki]
PubMed ID:http://aac.asm.org/content/38/1/49.abstract
